

# Index

- ABO compatibility, liver  
 transplantation 354–5, 359
- accessory cells, *see* antigen-presenting cells
- acetaldehyde adducts 376–7
- adenovirus 12 100, 252
- adhesion molecules 29–33  
 cytokine-induced expression 39–40  
 liver graft rejection and 368–9  
 memory T cells 38, 39
- adjuvants 211
- agammaglobulinaemia, X-linked (XLA) 169, 171, 174
- AIDS (acquired immunodeficiency syndrome) 178–98  
*see also* human immunodeficiency virus
- alcoholic liver disease 286, 376–7
- alpha heavy chain 224–5
- $\alpha_4\beta_1$  integrin (VLA-4) 30–1, 34
- $\alpha_4\beta_7$  integrin 30, 31–2, 38
- $\alpha_5\beta_1$  integrin 30, 32
- $\alpha_1\beta_2$  integrin, *see* LFA-1
- 5-aminosalicylic acid (5-ASA) 131, 134, 257
- aminotransferases, serum (AST)  
 acute viral hepatitis 329  
 auto-immune hepatitis 271, 276, 277  
 chronic viral hepatitis 281, 284–5
- anal intercourse 190
- anaphylaxis, *see* immediate hypersensitivity
- angioedema, hereditary 175
- animal models  
 auto-immune chronic gastritis 78–9  
 HLA gene expression 254  
 small bowel transplantation 236–7
- anti-CD3 monoclonal antibodies 360
- anti-CD4 monoclonal antibodies 259, 360–1
- anti-CD7 monoclonal antibodies 361
- anti-CD25 monoclonal antibodies 361
- anti-idiotypic antibodies 262
- anti-inflammatory therapies 262–4
- anti-lymphocyte globulin 243
- anti-metabolites 260–1
- anti-mitochondrial antibodies (AMA) 285  
 auto-immune hepatitis 271, 272, 306  
 primary biliary cirrhosis 301, 306;  
 antigen recognised by 307;  
 role 307–8  
 subtypes 285, 306
- anti-neutrophil cytoplasmic antibodies, perinuclear (pANCA) 122–3, 249–50, 251
- antibiotics, inflammatory bowel disease 118
- antibodies, *see* immunoglobulin(s)
- antibody-dependent cytotoxicity (ADCC)  
 auto-immune hepatitis 273  
 CD4 T cell-directed, HIV infection 188  
 food allergy 160
- antigen-presenting cells (APCs; accessory cells) 257, 258  
 HIV infection 181, 187  
 lamina propria 13  
 liver grafts 356–7, 369  
 Peyer's patches 5–6  
*see also* intestinal epithelial cells
- antigens  
 gut response 48, 49  
 oral tolerance 16–17  
 oral tolerisation therapy 17–18  
 presentation/recognition 257–9  
 uptake by gut 15–16, 153–6; cows' milk protein intolerance 155–6;  
 immunological factors  
 controlling 15–16;  
 infants/neonates 15, 153–5;  
 mechanisms 15

## INDEX

383

- antinuclear antibodies (ANA) 271–2, 274, 285
- apoptosis, HIV-induced 188–9
- arteriopathy, liver graft rejection 358
- arthropathy 275, 305
- asialoglycoprotein receptor (ASGP-R) auto-antibodies  
 auto-immune hepatitis 272–3, 275, 378  
 chronic hepatitis B 280
- aspirin ingestion 76
- auto-antibodies 248–51  
 alcoholic liver disease 286  
 auto-immune chronic gastritis 77–8  
 auto-immune hepatitis 271–3  
 chronic active hepatitis 285–6  
 chronic hepatitis B 279–80  
 chronic hepatitis C 283–4  
 coeliac disease 105, 249  
 hepatitis D 344  
 inflammatory bowel disease 122–3, 249–51  
 primary biliary cirrhosis 306–7  
 auto-immune cholangitis/  
 cholangiopathy 285–6
- auto-immune chronic active hepatitis (AIH) 269, 270–7, 283, 377–8  
 clinical features 270–1  
 differential diagnosis 285–6  
 extrahepatic manifestations 275–6  
 genetics and immunoregulation 273  
 hepatitis A and 326  
 hepatitis C and 274, 283, 341, 379  
 humoral and cellular mechanisms 271–3, 306  
 primary biliary cirrhosis overlap 272, 285, 300  
 sub-types 274–5, 378  
 treatment and prognosis 276–7, 378
- auto-immune chronic gastritis (AIG) 77–9, 89
- azathioprine 260, 276–7, 311
- B cells**  
 HIV infection 187  
 lamina propria 13–14  
 migration to gut 24–8  
 neuropeptides and 57–9  
 Peyer's patches 3, 5
- bacteria**  
 enteropathogenic 207–9  
 transplanted small bowel 239
- bacterial overgrowth, common variable immunodeficiency 173
- bcl-1 oncogene 228
- $\beta_1$  integrins 36  
 memory T cells 38, 39
- $\beta_2$ -microglobulin 333, 342, 358
- bile ducts**  
 primary biliary cirrhosis 303–4, 374  
 vanishing, liver graft rejection 358–9, 368
- bile salts, common variable immunodeficiency** 173
- biliary epithelium, HLA expression**  
 liver graft rejection 358, 368  
 primary biliary cirrhosis 309–10, 313
- bilirubin, serum, primary biliary cirrhosis** 302, 303
- biodegradable microparticles, oral immunisation** 213
- bombesin** 60
- bovine serum albumin (BSA)** 17
- breast feeding, inflammatory bowel disease and** 119, 120
- bronchus-associated lymphoid tissue (BALT)** 8–9
- Burkitt's lymphoma** 228–9
- C reactive protein (CRP), serum** 255
- calcitonin gene-related peptide (CGRP)** 51, 60
- Campylobacter* 207–8, 209
- carrageenan-induced colitis** 118
- CD4 antigen** 181
- CD4+ T cells (helper T cells)** 257, 258  
 activation 259, 260  
 classification 62–3, 163, 254  
 gliadin-specific 103, 106  
 hepatitis B 330, 334  
 hepatitis C 342  
 HIV enteropathy 192  
 HIV infection 181–2, 184, 186–9;  
 drug reactions and 197–8;  
 mechanisms of loss 187–9
- inflammatory bowel disease** 125
- intestinal epithelium** 11, 12
- lamina propria** 11–13
- liver graft rejection** 369
- migration to gut** 28–9
- primary biliary cirrhosis** 308
- therapies directed to** 257–9
- CD8+ T cells** 257, 258  
 coeliac disease 105–6  
 hepatitis A 325  
 hepatitis B 330, 334  
 HIV enteropathy 192  
 inflammatory bowel disease 125

- CD8+ T cells—*continued*  
 intestinal epithelium 11, 12  
 liver graft rejection 369  
 migration to gut 28–9  
 primary biliary cirrhosis 308, 309  
*see also* cytotoxic T cells
- CD11a/CD18, *see* LFA-1
- CD45 isoforms 36
- CD45R0+ T cells (memory T cells)  
 adhesion molecules 38, 39  
 coeliac disease 103  
 HIV enteropathy 192  
 inflammatory bowel disease 125  
 intestinal epithelium 11, 37  
 lamina propria 11–13, 37  
 migration to gut 36–8
- CD45RA+ T cells (naive T cells) 36–8, 39
- CD54, *see* ICAM-1
- central nervous system (CNS)  
 influences 61–2
- centrocyte-like cells (CCL)  
 MALT lymphomas 219, 220, 221–2, 223, 225  
 Peyer's patches 2–3
- centromere antibodies 307
- children  
 chronic hepatitis B 332  
 diarrhoeal diseases 207, 209  
 small bowel transplantation 240, 241  
*see also* infants/neonates
- chlorambucil 312
- chloride (Cl<sup>-</sup>) secretion, intestinal  
 lumen 53–5, 63–4
- cholangiopathy, auto-immune 285–6
- cholangitis  
 auto-immune 285–6  
 intrahepatic sclerosing 174  
 primary sclerosing, *see* primary sclerosing cholangitis
- cholecystokinin (CCK) 50, 56, 60
- cholera, *see* *Vibrio cholerae*
- cholera toxin (CT) 208, 212–13
- chronic active hepatitis (CAH) 269–86  
 auto-immune, *see* auto-immune chronic active hepatitis  
 cryptogenic 269, 270, 274, 277  
 drug-induced 270, 286, 376  
 metabolic 270, 286  
 viral 269, 270, 278–85
- chronic granulomatous disease (CGD) 175
- cirrhosis 270  
 alcoholic 376–7  
 primary biliary, *see* primary biliary cirrhosis
- coeliac disease (CD) 95–107  
 associated T cell lymphoma 229–32  
 genetic studies 95–9  
 HLA associations 97–9, 105, 253  
 immunoglobulin genes and 99  
 immunological changes 102–5, 153, 249, 252  
 morphological lesions 101  
 pathogenesis 101–2, 105–7  
 primary biliary cirrhosis and 305  
 primary immunodeficiency and 173  
 therapeutic strategies 255, 259, 260
- colchicine 312
- colic, infantile 150, 155–6
- colitis  
 carrageenan-induced 118  
 food-sensitive 159–60, 248  
 primary immunodeficiency 174  
 ulcerative, *see* ulcerative colitis
- colon  
 antibodies 122, 250  
 epithelial cell 40 kD protein  
 antibodies 122, 123, 251  
 immediate hypersensitivity 156–9  
 lymphoid tissue 6–7  
 lymphomas 219
- common variable immunodeficiency (CVI) 169  
 gastric disorders 170, 171  
 intestinal disorders 171, 172–3, 174  
 liver/gall-bladder disease 174–5
- complement  
 activation, regulators (RCA) 362  
 chronic *H. pylori* gastritis 82  
 coeliac disease 104–5  
 deficiency 175  
 inflammatory bowel disease 124  
 primary biliary cirrhosis 306
- corticosteroids  
 auto-immune hepatitis 276, 277  
 chronic hepatitis B 280–1, 337  
 inflammatory bowel disease 131, 134  
 lymphocyte migration and 40  
 mechanism of action 257, 259–60, 262  
 primary biliary cirrhosis 310
- cows' milk allergy (CMA) 16, 148–53  
 associated food intolerance 149  
 colitis 160  
 delayed-onset 152–3  
 diagnosis 150–1  
 gut permeability 155–6  
 immediate-onset 150, 151–2

## INDEX

385

- immunological basis 153–5
- mucosal morphology 151–3
- pathogenesis 160
- symptoms 148, 151
- cows' milk proteins, antibodies in
  - infants 16, 161
- CREST syndrome 305, 307
- Crohn's disease 114–36
  - adhesion molecule expression 39–40
  - cytokines 131–6, 255
  - environmental factors 115–21
  - epithelial cell function 128–9
  - genetic factors 114–15, 254
  - humoral immunity 121–4
  - hypersensitivity reactions 252, 253–4
  - infective agents 115–18
  - lymphocytes 124–8
  - macrophages/monocytes 129–31
  - therapeutic strategies 255–6, 257, 259, 260, 261
- chromoglycate, disodium 159, 248
- cross-matching, liver
  - transplantation 355
- cryoglobulinaemia 284
- essential mixed (EMC) 284
- crypt hyperplasia 101–2, 152–3
- cryptococcal meningitis 193
- cryptosporidiosis 172
- cutaneous lymphocyte antigen (CLA) 30, 34
- cyclosporin A 261
  - inflammatory bowel disease 134, 261
  - liver transplantation 359–60
  - primary biliary cirrhosis 311–12
  - small bowel transplantation 241–2
- cytochrome P450 IID6 (P450dbl) 272, 341
- cytokines 62–6, 254–5
  - epithelial function and 63–4
  - food-sensitive enteropathies 163–4
  - HIV enteropathy 192
  - inflammatory bowel disease 131–6, 255
  - intestinal epithelial cell-derived 9–10, 64
  - lymphocyte migration and 39–40
  - mucus and IgA secretion and 64–5
  - nerve interactions 65–6
  - therapies directed against 261–2
- cytomegalovirus (CMV) infection 358–9, 370
- cytotoxic T cells (Tc; CTL)
  - chronic hepatitis B 330–1, 334
  - hepatitis C 341–2
  - HIV infection 185, 188
  - inflammatory bowel disease 127
  - intestinal infections 206–7
  - see also* CD8+ T cells
- delayed-type hypersensitivity (DTH; type IV)
  - food-sensitive enteropathies 162–3
  - intestinal diseases 252–5
- dendritic cells
  - HIV infection 181, 185
  - lamina propria 13
  - liver grafts 369
  - Peyer's patches 5–6
- dermatitis herpetiformis (DH) 101, 252
- diabetes mellitus, insulin-dependent (IDDM) 275
- diarrhoea
  - HIV infection 191–2
  - infectious 207–10
  - primary immunodeficiencies 171, 175
- diet, inflammatory bowel disease and 118–20
- dietary therapies 255–6
- disodium chromoglycate 159, 248
- drug reactions
  - chronic active hepatitis 270, 286, 376
  - HIV infection 197–8
  - liver disease 374–6
  - primary biliary cirrhosis 372
- dyspepsia, *H. pylori* and 88
- E-selectin (ELAM-1) 31, 34, 58
  - cytokine-induced expression 39–40
- E2 antigen 285, 307
  - primary biliary cirrhosis and 307–8, 373
- eicosanoids, coeliac disease 104
- ELAM-1, *see* E-selectin
- endomysial antibodies 105, 249
- endothelial cells
  - adhesion molecules 31–2, 33–4
  - lymphocyte adhesion to 29–34
- enteric nerves
  - HIV infection 192
  - transmural stimulation (TS) 53, 54–5
- enteric nervous system (ENS) 48–51
- enterobacterial common antigen (Kunin antigen) 117–18
- enteroglucagon 50
- enteropathy-associated T cell lymphoma (EATL) 229–32
- enteroviruses 209, 212
- eosinophilic gastritis 79, 80

- eosinophilic gastroenteropathy/  
 gastroenteritis 248
- eosinophils  
 coeliac disease 103–4, 106–7  
 ulcerative colitis 248
- epithelial cell 40kD protein  
 antibodies 122, 123, 251
- epithelial cell associated component  
 (ECAC) antibodies 122, 123
- epithelial cells, intestinal, *see* intestinal  
 epithelial cells
- epithelium  
 biliary, *see* biliary epithelium  
 follicle-associated 1, 2–3, 6–7  
 gut, *see* intestinal epithelium
- Escherichia coli*  
 enteropathogenic 207–8  
 enterotoxigenic 205–6, 207–8  
 rough mutants 306, 373
- experimental auto-immune  
 encephalomyelitis (EAE) 18, 257
- fibroblasts 60
- fibronectin 30
- FK506  
 liver transplantation 315, 360, 370  
 small bowel transplantation 242
- follicle-associated epithelium (FAE) 1,  
 2–3, 6–7
- food allergy 147–64, 248, 255  
 definition 147  
 foods commonly involved 148, 149  
 pathogenesis 153–64  
*see also* cows' milk allergy
- food aversion 147
- food intolerance 147–64  
 definition 147–8  
 foods commonly involved 148, 149  
 pathogenesis 153–64  
 small intestinal mucosal  
 morphology 152–3
- 4F2 T cell activation marker 125–6
- Freund's adjuvant, complete 211
- fulminant hepatic failure 345
- gall-bladder disease, primary  
 immunodeficiency 174–5
- gastric carcinoma  
 chronic *H. pylori* infection and 81  
 common variable  
 immunodeficiency 171
- gastric lymphomas  
 high grade 226–7  
 low grade 218–19, 222–3, 224
- gastrin 50, 60
- gastrin inhibitory peptide (GIP) 50
- gastrin-receptor auto-antibodies 77
- gastrin-releasing peptide (GRP) 50, 60
- gastritis 76–90  
 acute 76–7  
 auto-immune chronic (AIG) 77–9,  
 89  
 chronic 77–90  
 chronic *H. pylori*, *see Helicobacter*  
*pylori*, chronic gastritis  
 eosinophilic 79, 80  
 lymphocytic 79–80, 81  
 varioliform 79–80
- genital infections, HIV infection  
 and 190–1
- giardiasis (*Giardia lamblia*) 209–10  
 primary immunodeficiencies 170,  
 171–2
- gliadin 252  
 antibodies 105  
 chemistry 100  
 specific T cells 103, 106
- gluten  
 enteropathy, *see* coeliac disease  
 withdrawal, antibody deficiencies 173  
*see also* gliadin
- GlyCAM-1 31, 34
- Gm haplotypes, coeliac disease 99
- goblet cell antibodies 122, 123, 250
- GOR peptide antibodies 283, 341
- gp90<sup>mel</sup>, *see* L-selectin
- gp120 (HIV envelope protein) 181, 187  
 CD4 T cell depletion and 188, 189  
 molecular mimicry 189
- graft-versus-host disease (GvHD)  
 liver transplantation 354–5, 359  
 small bowel transplantation 235,  
 238–9, 242
- graft-versus-host reaction (GvHR) 162,  
 163
- granulomatous disease, chronic  
 (CGD) 175
- gut-associated lymphoid tissue  
 (GALT) 1–9, 48  
 HIV infection 190  
 lymphocyte migration to 24–9  
 memory T cells 37
- halothane-induced liver disease 374–6
- Helicobacter felis* 90
- Helicobacter pylori*  
 acute gastritis 76–7  
 antigens 85

## INDEX

387

- chronic gastritis 77, 80–90; local  
 cellular immune response 8, 82–4,  
 87, 219; local humoral response 82;  
 pathological mechanisms 88–9;  
 systemic immune responses 84–5;  
 treatment prospects 90  
 gastric lymphoma and 219  
 serological studies 86–8  
 transmission 81–2  
 helper T cells, *see* CD4+ T cells  
 hepatic failure, fulminant 345  
 hepatitis  
 alcoholic 377  
 chronic active, *see* chronic active  
 hepatitis  
 drug-related 374–6  
 non-A, non-B (NANB) 174, 281  
 primary immunodeficiency 174  
 hepatitis A (HAV) 324–7  
 hepatitis B (HBV) 327–38  
 acute 327–33; immune  
 responses 329–30; mechanisms of  
 immunological injury 330–3  
 chronic 278–81, 333–4, 378–9; clinical  
 features 278–9; extrahepatic  
 manifestations 280; immunological  
 mechanisms 279–80, 330–3; liver  
 transplantation 361, 379;  
 treatment 280–1, 337, 378–9  
 delta virus superinfection 278–9, 280,  
 337, 343–4  
 HIV infection 198  
 primary immunodeficiency 174  
 vaccination 337–8  
 virology 328  
 virus variants 334–6  
 hepatitis C (HCV) 339–42, 379  
 acute 339, 340  
 antibodies 282–3, 339–40  
 auto-immune hepatitis and 274, 283,  
 341, 379  
 chronic 274, 281–5, 339, 340;  
 extrahepatic manifestations 284;  
 humoral/cellular mechanisms  
 282–4; treatment 284–5  
 mechanisms of tissue damage 341–2  
 vaccination 342  
 hepatitis delta virus (HDV) 278–9, 280,  
 337, 342–4  
 hepatitis E 344–6  
 hepatocytes, HLA expression 309, 357,  
 368  
 15-HETE 104  
 HIV, *see* human immunodeficiency virus
- HLA  
 chronic hepatitis B and 330, 331, 334  
 disease patterns and 253–4  
 liver graft rejection and 356–7  
 matching, liver transplantation 355  
 therapies directed against 259  
 HLA associations  
 auto-immune chronic gastritis 79  
 auto-immune hepatitis 273, 274–5  
 coeliac disease 97–9, 105, 253  
 hepatitis B vaccine responders 338  
 inflammatory bowel disease 115,  
 253–4  
 primary biliary cirrhosis 299, 372  
 HLA-B27 254  
 HLA class I molecules 257, 258  
 hepatitis B 334  
 HIV envelope proteins and 189  
 liver graft rejection and 357, 358, 368  
 primary biliary cirrhosis 309, 313  
 HLA class II molecules 257, 258  
 gut epithelial cells, *see* intestinal  
 epithelial cells, HLA class II  
 expression  
 hepatitis B 334  
 HIV envelope proteins and 189  
 inflammatory bowel disease 128–9  
 lamina propria 13  
 liver graft rejection and 368  
 M-cells 3  
 Peyer's patches 5–6  
 primary biliary cirrhosis 309–10, 313  
 HLA-DP, coeliac disease 98  
 HLA-DQ, coeliac disease 97–8  
 HLA-DR  
 auto-immune hepatitis 273, 274  
 coeliac disease 97–8  
 Hodgkin's disease 217  
 human immunodeficiency virus (HIV)  
 cytopathic effects 183–4  
 enteropathy 191–2  
 gp120 envelope protein, *see* gp120  
 immune response 184–6  
 mechanism of cellular infection 181–3  
 molecular mimicry 189  
 type 1 (HIV-1) 180  
 type 2 (HIV-2) 180, 182, 184  
 virology 180–1  
 human immunodeficiency virus (HIV)  
 infection 178–98  
 CD4 T cell depletion, *see* CD4+ T  
 cells, HIV infection  
 crypt hyperplasia 102  
 drug reactions 197–8

- human immunodeficiency virus (HIV)  
 infection—*continued*  
 gastrointestinal tract 190–8; initial  
 infection via 7, 190–1;  
 manifestations 193–7; non-HIV-  
 related infections/diseases 198;  
 opportunist infections/tumours 193,  
 194–5  
 hepatitis B vaccination 338  
 immunopathogenesis 186–7  
 human leukocyte antigens, *see* HLA  
 hyaluronic acid 358  
 hypergammaglobulinaemia  
 auto-immune hepatitis 271  
 HIV infection 187  
 hypersensitivity 247  
 type I, *see* immediate hypersensitivity  
 type II: food allergy 160; intestinal  
 diseases 248–51  
 type III: food-sensitive  
 enteropathies 161; intestinal  
 diseases 251–2  
 type IV, *see* delayed-type  
 hypersensitivity  
 hypogammaglobulinaemias,  
 primary 170–5  
 hypothyroidism 305
- ICAM-1 31, 33  
 cytokine-induced expression 39–40  
 hepatitis B 334  
 liver graft rejection 369  
 primary biliary cirrhosis 309  
 ICAM-2 31, 33
- IgA  
 chronic *H. pylori* gastritis 82, 84,  
 86  
 coeliac disease 105  
 deficiency 170, 174  
 immune exclusion 16, 206  
 immunoproliferative small intestinal  
 disease 225  
 inflammatory bowel disease  
 121–2  
 protective function 206  
 secretion, regulation 55–6, 64–5
- IgE  
 cows' milk allergy and 150–2  
 food-sensitive colitis 159–60, 248  
 type I hypersensitivity reactions  
 156–9, 248
- IgG  
 chronic *H. pylori* gastritis 82, 84  
 inflammatory bowel disease 121
- IgM  
 chronic *H. pylori* gastritis 82, 84–5  
 deficiency 174  
 immediate hypersensitivity (type I) 248  
 psychological influences 61–2  
 small bowel and colon 156–9
- immune complexes  
 food-sensitive enteropathies 161  
 hepatitis B 329  
 intestinal diseases 251–2  
 primary biliary cirrhosis 305–6
- immune exclusion 15–16, 206
- immuno-neuroendocrine system, *see*  
 neuroendocrine-immune system
- immunodeficiency  
 common variable (CVI), *see* common  
 variable immunodeficiency  
 primary (PID) 169–75  
 secondary 178–98  
 severe combined (SCID), *see* severe  
 combined immunodeficiency
- immunoglobulin(s)  
 chronic *H. pylori* gastritis 82, 84–5  
 coeliac disease 105  
 deficiency syndromes 170–5  
 gene rearrangements 224, 227, 229  
 hepatitis B 279–80, 329  
 hepatitis C 282–4  
 human serum (ISG) 326  
 inflammatory bowel disease 121–3  
 lamina propria plasma cells 14  
 Peyer's patches 5  
 synthesis, neuropeptides and 56,  
 57–9  
 transport to gut lumen 10, 56  
*see also* auto-antibodies; IgA; IgE;  
 IgG; IgM
- immunoglobulin genes, coeliac  
 disease 99
- immunoglobulin-like adhesion  
 molecules 29–33
- immunoglobulin receptor, polymeric  
 (secretory component) 10, 358
- immunoproliferative small intestinal  
 disease (IPSID) 224–6
- immunosuppressed patients, chronic  
 hepatitis B 332–3
- infantile colic 150, 155–6
- infants/neonates  
 chronic hepatitis B 332  
 cows' milk protein antibodies 16, 161  
 dietary antigen uptake 15, 153–6  
 food-sensitive colitis 248  
*see also* cows' milk allergy

## INDEX

389

- infections  
 intestinal, *see* intestinal infections  
 opportunistic, HIV infection 193, 194–5
- infective agents, inflammatory bowel disease 115–18
- inflammation  
 lymphocyte migration into gut 39–40  
 therapies directed against 262–4
- inflammatory bowel disease (IBD)  
 114–36  
 cytokines 131–6, 255  
 environmental factors 115–21  
 epithelial cell function 128–9  
 genetic factors 114–15  
 humoral immunity 121–4  
 hypersensitivity reactions 252, 253–4  
 infective agents 115–18  
 interleukin-1/substance P interactions 65–6  
 lymphocytes 124–8  
 macrophages/monocytes 129–31  
 neuronal degeneration 52  
 psychological factors 61  
 therapeutic strategies 261, 262–3  
*see also* Crohn's disease; ulcerative colitis
- integrins 29–33  
 memory T cells 38, 39
- interferon- $\alpha$  (IFN- $\alpha$ ) 59, 63  
 acute hepatitis B 330  
 chronic hepatitis B 281, 333, 337, 378–9  
 hepatitis C 284–5, 340
- interferon- $\beta$  (IFN- $\beta$ ) 59, 63
- interferon-gamma (IFN- $\gamma$ ) 63, 259, 260  
 coeliac disease 101–2, 106  
 cryptosporidiosis 172  
 hepatitis A 325  
 hepatitis B 333  
 HIV infection 198  
 IgA secretion and 64  
 inflammatory bowel disease 134, 255  
 intestinal epithelial function and 64  
 intestinal infections 207  
 lymphocyte migration and 39, 40
- interleukin-1 (IL-1) 63, 255, 259, 260  
 acute hepatitis B 330  
 inflammatory bowel disease 131, 132  
 intestinal epithelial function and 63–4  
 lymphocyte migration and 39  
 mucus secretion and 64  
 nerve interactions 65–6  
 receptor antagonist (IL1ra) 131, 262
- interleukin-2 (IL-2) 59, 259, 260  
 HIV infection 189  
 IgA secretion and 64  
 inflammatory bowel disease 131, 133, 255  
 liver graft rejection and 357
- interleukin-2 receptors (IL2R)  
 coeliac disease 103, 104  
 inflammatory bowel disease 125–6, 131, 133  
 liver graft rejection 357–8
- interleukin-4 (IL-4) 40
- interleukin-5 (IL-5) 103
- interleukin-6 (IL-6)  
 chronic *H. pylori* gastritis 83–4  
 epithelial cell synthesis 64  
 inflammatory bowel disease 132, 134
- interleukin-8 (IL-8) 83, 133
- intestinal diseases, immunologically-mediated 247–64  
 clinical aspects 247–55  
 rationale for therapy 255–64
- intestinal epithelial cells  
 antigen presentation 9–10;  
 inflammatory bowel disease 128–9  
 cytokines 9–10, 64; LA class II expression 9, 10; coeliac disease 104; inflammatory bowel disease 128–9  
 non-specific defences 205
- intestinal epithelium 9–11  
 immunological role 9–10, 130  
 ion secretion, regulation 53–5, 63–4  
 lymphoid cells, *see* intraepithelial lymphocytes  
 permeability 55, 154–6
- intestinal infections 204–14  
 bacterial 207–9  
 HIV infection 193–7, 198  
 immunisation 210–14; oral 211–14; parenteral 210–11  
 non-specific defence mechanisms 204–6  
 parasitic 209–10  
 primary immunodeficiencies 171–2, 175  
 specific immune reactions 206–7  
 viral 209
- intestine, lymphocyte migration to 24–41
- intraepithelial lymphocytes (IEL)  
 10–11, 12  
 adhesion 32  
 coeliac disease 102, 106, 153



- intraepithelial lymphocytes (IEL)—  
*continued*  
 food-sensitive enteropathies 153  
 giardiasis 210  
 inflammatory bowel disease 127–8,  
 129  
 intestinal infections 206–7  
 memory T cells 11, 12, 37  
 migration pathways 24–5, 27, 28  
 intravenous immunoglobulin (IVIg) 174  
 intrinsic factor (IF)  
 antibodies 77, 249  
 deficiency 170  
 ion secretion, intestinal lumen 53–5,  
 63–4
- jejunitis, ulcerative 230  
 Johne's disease 115
- K99 antigen 208  
 Kaposi's sarcoma 193–7  
 Kunin antigen 117–18  
 Kupffer cells, liver grafts 369
- L-selectin 30, 33–4  
 memory T cells 38, 39  
 $\alpha$ -lactalbumin 155–6  
 $\beta$ -lactoglobulin 155  
 LAM-1, *see* L-selectin  
 lamina propria 11–14  
 accessory cells 13  
 lymphocytes (LPL); B cells 13–14;  
 coeliac disease 103, 106; cytokine  
 synthesis 163; inflammatory bowel  
 disease 125; intestinal  
 infections 207; migration  
 pathways 24–5, 26–7, 28, 29; T  
 cells 11–13, 37  
 Langerhans' cells, HIV infection 181  
 large intestine, primary  
 immunodeficiencies and 171–4  
 LECAM-1, *see* L-selectin  
 leishmaniasis 254–5  
 leprosy 253, 254  
 Leu-8 antigen, *see* L-selectin  
 LFA-1 ( $\alpha_1\beta_2$  integrin) 30, 32–3, 34  
 hepatitis B 334  
 lymphoblast uptake by gut and 36  
 memory T cells 38  
 lipid A, *H. pylori* 82  
 5-lipoxygenase (5-LPO) inhibitors  
 262–3  
 liver, massive haemorrhagic  
 necrosis 356, 370
- liver disease  
 alcoholic 286, 376–7  
 drug-related 374–6  
 immunopathogenesis 366–79  
 primary immunodeficiency 174–5  
*see also* hepatitis
- liver–kidney microsomal antibodies  
 (LKM)  
 chronic hepatitis C 274, 283, 341,  
 379  
 type 1 (LKM-1), auto-immune  
 hepatitis 271, 272, 274–5, 277, 379  
 type 3 (LKM-3) 279
- liver/small bowel transplantation,  
 combined 236–7, 241–2
- liver transplantation 354–62, 366–71  
 chronic hepatitis B 361, 379  
 graft rejection 356–9, 362, 366–70;  
 acute 356–7, 367–8; chronic  
 (ductopenic) 358–9, 367, 368, 370;  
 hyperacute 356, 362, 367, 370;  
 immunological indices 357–8, 367,  
 370; immunopathogenesis 368–70  
 graft-versus-host disease 354–5, 359  
 hepatitis D recurrence 343–4  
 immunosuppressive therapy 359–61,  
 370–1  
 primary biliary cirrhosis 313–14; post-  
 transplant recurrence 314–15, 372  
 recipient selection 354–5  
 xenografts 361–2
- lupus erythematosus (LE) cells 271–2
- lymphoblasts 34–6
- lymphocyte function-associated antigen 1,  
*see* LFA-1
- lymphocytes  
 adhesion molecules 30, 34  
 endothelial cell interactions 29–34  
 inflammatory bowel disease 124–8  
 intraepithelial, *see* intraepithelial  
 lymphocytes  
 lamina propria, *see* lamina propria,  
 lymphocytes  
 migration to intestine 24–41  
 therapies directed against 261–2  
*see also* B cells; T cells
- lymphocytic gastritis 79–80, 81  
 lymphoepithelial lesions 221, 222
- lymphoid aggregates  
 chronic *H. pylori* gastritis 8, 82–3, 87,  
 219  
 primary biliary cirrhosis 304
- lymphoid hyperplasia, nodular  
 (NLH) 172–3

## INDEX

391

- lymphoid tissue  
 bronchus-associated (BALT) 8–9  
 colon 6–7  
 gut-associated (GALT), *see* gut-associated lymphoid tissue  
 HIV infection 185  
 mucosa-associated (MALT), *see* mucosa-associated lymphoid tissue  
 small intestine 1–6  
 stomach 7–8  
 lymphoma 217–32  
 Burkitt's 228–9  
 classification 218  
 enteropathy-associated T cell (EATL) 229–32  
 HIV infection 197  
 malignant, mantle cell type (centrocytic) 227–8  
 mucosa-associated lymphoid tissue (MALT) 9, 218; high grade 226–7; immunoproliferative small intestinal disease (IPSID) 224–6; low grade B cell 218–24  
 staging 217–18  
 lymphomatous polyposis 227–8  
 lymphoplasmapheresis 261
- M-cells 3, 7, 15, 155  
 HIV infection and 7, 190
- macrophages  
 chronic *H. pylori* gastritis 83  
 coeliac disease 103  
 HIV infection 181  
 inflammatory bowel disease 129–31  
 lamina propria 13  
 neural interactions 58, 65
- MadCAM-1 31–2, 33, 36
- major histocompatibility complex (MHC)  
 genes 96–7  
 molecules, *see* HLA
- malabsorption  
 enteropathy-associated T cell lymphoma 229–30  
 HIV infection 191–2  
 primary immunodeficiency 171, 175
- malotilate 313
- mantle cell lymphoma 227–8
- massive haemorrhagic necrosis, liver 356, 370
- mast cells (MCs) 53–5  
 coeliac disease 104  
 food allergy 152, 158–9  
 mediators 53, 55  
 nerve growth factor and 60  
 neural interactions 51–2, 54–5
- mediators  
 coeliac disease 104  
 immune cell 62–6
- membranous nephritis, chronic hepatitis B 280
- memory cells 34, 35, 36–8
- memory T cells, *see* CD45RO+ T cells
- 6-mercaptopurine 260
- methotrexate 261, 313
- microglia, HIV infection 181
- migration, lymphocyte, to intestine 24–41  
 cellular and molecular biology 29–34  
 immunisation events and 34–6  
 inflammatory events and 39–40  
 memory T cells 36–8  
 physiology 24–9  
 small bowel grafts 237–8
- mitochondrial antibodies, *see* anti-mitochondrial antibodies
- molecular mimicry 254  
 HIV envelope proteins 189
- monoclonal antibodies  
 liver transplantation 360–1, 371  
 small bowel transplantation 243  
 therapeutic potential 259, 262
- monocytes  
 HIV infection 181  
 inflammatory bowel disease 129–31  
*see also* macrophages
- motilin 50
- mucosa-associated lymphoid tissue (MALT) 8–9  
 lymphomas, *see* lymphoma, mucosa-associated lymphoid tissue
- mucosal lymphocyte antigen (MLA) 32
- mucus  
 gastric secretion, *H. pylori* infection 88–9  
 protective function 205–6  
 regulation of secretion 55–6, 64–5
- multiple sclerosis 18
- c-myc oncogene 229
- mycobacteria, inflammatory bowel disease 115–16  
*Mycobacterium paratuberculosis* 115–16  
*Mycobacterium tuberculosis*, AIDS 193
- myelin basic protein (MBP) 18
- naive T cells (CD45RA+) 36–8, 39
- natural killer (NK) cells  
 inflammatory bowel disease 127

- natural killer (NK) cells—*continued*  
 intestinal infections 207  
 primary biliary cirrhosis 308–9  
 neonates, *see* infants/neonates  
 nerve growth factor (NGF) 59–60  
 nerves  
   cytokine interactions 65–6  
   immune cell contacts 51–3  
 neuroendocrine-immune system 48–67  
   CNS influences 61–2  
   functional studies 53–61  
   immune cell mediators and 62–6  
   morphological studies 51–3  
 neurokinin A (NKA) 58  
 neuropeptide Y (NPY) 50, 53, 60  
 neuropeptides 50, 56–61  
   epithelial ion secretion and 53  
   immunoglobulin synthesis/secretion  
   and 56  
   leukocyte synthesis 57, 60–1  
   mast cell activation 55  
   mucus secretion and 55  
 neurotensin (NT) 50, 55  
 neurotransmitters 50, 55  
 neutrophils  
   chronic *H. pylori* gastritis 83–4  
   celiac disease 104  
   substance P and 58  
*Nippostrongylus brasiliensis* 51, 52, 64  
 nitric oxide (NO) 53–4  
 nodular lymphoid hyperplasia  
 (NLH) 172–3  
 non-Hodgkin's lymphoma 217, 218  
 non-specific defence mechanisms  
 204–6  
 nutrition  
   inflammatory bowel disease and  
   118–20  
   total parenteral (TPN) 240–1  
 OKT3 monoclonal antibodies 360  
 2',5'-oligoadenylate synthetase (2–5  
 AS) 333  
 opportunistic infections/tumours, HIV  
 infection 193, 194–5  
 oral disorders, primary deficiency 170  
 oral immunisation 211–14  
 oral tolerance 16–17  
 oral tolerisation therapy 17–18  
 osteoporosis, steroid-induced 310  
 ovalbumin 155  
 2-oxo-acid dehydrogenase enzyme  
 complex (2-OADH) auto-  
 antibodies 307  
 P-selectin 34  
 pan-T cell monoclonal antibody, ricin A  
 chain-conjugated 243  
 parasites, intestinal 209–10  
 parenteral nutrition, total (TPN)  
 240–1  
 parietal cell antibodies (PCA) 77, 249  
 parietal cell microsomal antibodies  
 (PCMA) 77, 78, 79  
 D-penicillamine 311  
 peptic ulceration 81, 87, 88  
 peptide histidine isoleucine (PHI) 50  
 peptide YY 50  
 peripheral lymph node (PLN)  
   addressin 31, 33–4  
 permeability, intestinal 55, 154–6  
 pernicious anaemia (PA) 77, 79, 249  
   -like disease, primary  
   immunodeficiency 170–1  
 Peyer's patches 1–6  
   histology 2–3  
   lymphocyte migration pathways 24–7,  
   28–9  
   lymphoid/myeloid cells 3–6  
 plasma cells  
   lamina propria 13–14  
   MALT lymphomas 219–21, 224–6  
   stomach 7  
 polyethylene glycol (PEG) 155  
 portal fibrosis, primary biliary  
 cirrhosis 304  
 portal hypertension 299, 300  
 postcapillary venules (PCV), lymphocyte  
 migration across 29  
 primary biliary cirrhosis (PBC) 298–315,  
 371–4  
   anti-mitochondrial antibody  
   negative 301–2, 373–4  
   associated auto-immune disease 305,  
   372  
   asymptomatic disease 301  
   auto-immune hepatitis overlap 272,  
   285, 300  
   clinical features 299–300  
   epithelial HLA expression 309–10  
   immunological abnormalities 305–9  
   incidence and geography 298–9  
   liver transplantation 313–14  
   medical treatment 310–13, 372  
   overlap syndromes 300  
   pathology 303–5  
   post-transplant recurrence 314–15,  
   372  
   prognosis 300–1, 302

## INDEX

393

- prognostic models 302–3  
 staging 304–5  
 primary sclerosing cholangitis (PSC) 123, 276, 374  
   differential diagnosis 285–6  
   HLA associations 115  
 prostaglandin E<sub>2</sub> 104  
 proton pump, gastric parietal cell 78, 249  
 psychoneuroimmunology 61–2  
  
 rectum, HIV infection via 190–1  
 regulators of complement activation (RCA) 362  
 rejection  
   liver grafts, *see* liver transplantation, graft rejection  
   small bowel grafts 239  
 renal transplantation 355  
 renal tubular acidosis 305  
 reoviruses 207  
 reticulin antibodies 249  
 Rhesus (Rh) antigens 17–18  
 rheumatoid arthritis 257, 259  
 rheumatoid factor 275, 326  
 rotaviruses 209, 212  
  
*Saccharomyces cerevisiae*, Crohn's disease and 121  
 salicylates 76, 262  
*Salmonella* 206, 207–8, 209  
*Salmonella typhi* vaccines 212  
 sarcoidosis 174, 300, 372  
 scleroderma 305, 307  
 secretory component 10, 358  
 selectins 33–4  
 severe combined immunodeficiency (SCID) 169, 175  
   mice 184, 308  
*Shigella* 206, 207–9, 212  
 sialyl Lewis X 30, 34  
 Sjögren's syndrome 9, 305  
 skin testing, cows' milk allergy 150–1  
 Slim disease 192  
 small bowel  
   immediate hypersensitivity 156–9  
   immunoproliferative small intestinal disease (IPSID) 224–6  
   lymphoid tissue 1–6  
   lymphoma 219  
   primary immunodeficiencies and 171–4  
   small bowel/liver transplantation, combined 236–7, 241–2  
   small bowel transplantation 235–43  
     case selection 240–1  
     experimental models 236–7  
     future prospects 242–3  
     graft physiology 235–6  
     graft rejection 162  
     immunology 237–9  
     isolated 241, 242  
     mucosal barrier/immunity 239  
     organ preservation 239–40  
   smoking 118, 119, 120  
   smooth muscle antibodies (SMA) 271, 272, 274, 285  
   somatostatin (SOM) 50, 55, 57, 59  
   stomach  
     lymphoid tissue 7–8  
     primary immunodeficiencies and 170–1  
   substance K 58  
   substance P (SP) 50, 51, 53, 57–8  
     cytokine interactions 65–6  
     mast cell activation 55  
   suppressor T cells, inflammatory bowel disease 126–7  
   systemic lupus erythematosus (SLE) 271–2  
  
 T-cell receptors (TcR)  
   CD4 T cell apoptosis and 189  
   intraepithelial lymphocytes 11;  
     coeliac disease 102, 106  
   lamina propria lymphocytes 11  
   therapies directed to 257  
 T cells  
   auto-immune chronic gastritis 79  
   chronic *H. pylori* gastritis 82–3  
   coeliac disease 103, 105–7  
   crypt hyperplasia and 101–2  
   food-sensitive enteropathies 162–3  
   hepatitis B 279, 329–30, 331  
   inflammatory bowel disease 124–8  
   intestinal epithelium 11, 12  
   intestinal infections 206–7  
   lamina propria 11–13, 37  
   liver graft rejection 357, 359  
   migration to gut 24–9  
   naive (CD45RA+) 36–8, 39  
   neuropeptides and 58, 59  
   Peyer's patches 3–5  
   *see also* CD4+ T cells; CD8+ T cells;  
     CD45RO+ T cells  
   *tap* 2 protein transporter gene 96–7, 98–9  
   TH-0 cells 62

- TH-1 cells 62, 254–5  
 TH-2 cells 62, 254  
   food allergy 159  
 tielinic acid 376  
 tolerance  
   hepatitis B antigens 332–3  
   oral 16–17  
 transforming growth factor- $\beta$  (TGF- $\beta$ ) 18, 40, 64  
 transmural stimulation (TS), enteric nerves 53, 54–5  
*Trichinella spiralis* 65  
 tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) 63, 255  
   chronic *H. pylori* gastritis 83  
   coeliac disease 99, 106  
   HIV infection 189  
   IgA secretion and 64  
   inflammatory bowel disease 135  
   intestinal epithelial function and 64  
   lymphocyte migration and 39, 40  
  
 ulcerative colitis (UC) 114–36  
   adhesion molecule expression 39–40  
   auto-immune hepatitis 276  
   auto-immune hypothesis 124  
   cytokines 131–6, 255  
   environmental factors 115–21  
   genetic factors 114–15, 254  
   HIV infection 198  
   humoral immunity 121–4, 249–51  
   hypersensitivity reactions 248, 252, 253–4  
   infective agents 115–18  
   lymphocytes 124–8  
   macrophages/monocytes 129–31  
   primary sclerosing cholangitis and 115, 123, 276  
   therapeutic strategies 256, 259–60, 261, 263  
 ulcerative jejunitis 230  
 University of Wisconsin (UW) solution 240  
 urease, *H. pylori* 88  
  
 urinary tract infections 306, 373  
 ursodeoxycholic acid (UDCA) 313, 374  
  
 vaccination  
   enteropathogens 210–14  
   hepatitis A 326–7  
   hepatitis B 337–8  
   hepatitis C 342  
 vanishing bile duct syndrome (VBDS) 358–9, 368  
 vasoactive intestinal peptide (VIP) 50, 53, 57, 58–9  
   mast cell activation 55  
 VCAM-1 30, 31  
   cytokine-induced expression 39, 40  
*Vibrio cholerae* (cholera) 205, 206, 207–8  
   oral vaccines 211–13  
   parenteral immunisation 211  
 villous atrophy  
   coeliac disease 95, 101, 106–7  
   delayed-type hypersensitivity and 162–3  
   dermatitis herpetiformis 101  
   food-sensitive enteropathies 153  
 viral hepatitis 378–9  
   acute 324–46  
   chronic 269, 270, 278–85  
   *see also specific viruses*  
   viruses, enteric 209, 212  
 vitamin B12 malabsorption 249  
 VLA antigens 30–1  
 VLA-1 11  
 VLA-4 ( $\alpha_4\beta_1$ , integrin) 30–1, 34  
  
 white cell scanning, isotope-labelled 255, 256  
 Wilson's disease 286  
  
 X-linked agammaglobulinaemia (XLA) 169, 171, 174  
 xenotransplantation, liver 361–2  
  
 zileuton 263